Monoclonal and Polyclonal Antibodies – Why Chickens Beat Mammals for Human Targets 

Antibodies are foundational tools in research, diagnostics, and therapeutics. Traditionally, they are classified into two main types, polyclonal and monoclonal, each with distinct characteristics, advantages, and limitations. 

Here at Immune Biosolutions, we offer production of monoclonal and polyclonal antibodies using our avian system which provides unique competitive advantages for the discovery of your antibodies. 

Monoclonal Antibodies: Evolutionary Distance Drives Epitope Diversity and Specificity

Monoclonal antibodies are derived from a single B cell clone and recognize a single epitope. They are highly specific, have excellent reproducibility and a defined molecular identity. They are the ideal candidates for diagnostics and therapeutic development. 

Our avian production system offers a competitive advantage to propel your antibody discovery projects forward: evolutionary distance with humans and other mammals.

Evolutionary distance plays a critical role in shaping the strength and diversity of the immune response. Because chickens are phylogenetically distant from humans, many human proteins, especially highly conserved ones, are perceived as strongly foreign antigens. This contrasts with mammalian hosts like mice or rabbits, where conserved human proteins may be weakly immunogenic due to sequence similarity and immune tolerance. As a result, chickens can mount a broader and more diverse antibody response, targeting epitopes that are often inaccessible in traditional systems, yielding highly specific monoclonal antibodies against challenging human targets. 

This expanded epitope recognition not only improves the likelihood of generating high-affinity binders but also enhances antibody diversity, improving the odds of identifying functional candidates across a range of applications. Notably, non-immunogenic and highly specific binders for humans and mice (cross-species reactive) can often be identified in chicken-based antibody discovery campaigns, significantly reducing preclinical costs by enabling the use of wild-type mice instead of expensive immunodeficient models. 

Egg Yolk-Derived Polyclonal Antibodies: High Yield, Diverse Epitopes, Cleaner Signal

Polyclonal antibodies are a heterogeneous mixture of immunoglobulins produced by different B cell clones in response to an antigen. Because they recognize multiple epitopes on the same target, they offer high sensitivity and robustness in applications such as ELISA or immunohistochemistry. However, this diversity comes at a cost. In standard production systems, polyclonal antibodies can have higher batch-to-batch variability which can compromise reproducibility, limited supply consistency due to reliance on individual animals, as well as cross-reactivity risks, especially in complex samples. In addition, polyclonal antibodies are typically generated by immunizing mammals (e.g., rabbits, goats), followed by repeated blood collection, an invasive process. However, these downsides can be mitigated through production in our avian system. 

Chickens naturally transfer large quantities of antibodies (IgY) into their egg yolks to provide passive immunity to their offspring. This biological process can be harnessed for non-invasive production of large quantities of antibodies, from multiple animals. Our system also reduces cross-reactivity; IgY do not bind mammalian Fc receptors or activate complement in the same way as IgG, reducing background noise. 

Depending on budget and target, we can deliver up to 30 mg of high-quality polyclonal antibodies, enough to support years of assays. Moreover, IgY antibodies have robust storage stability, allowing long-term preservation. 

For questions or to discuss your antibody projects, visit our website or get in touch with our team.